Clinical Trials Sponsored by Rigel Pharmaceuticals

Total 19920 results

Kissei Pharmaceutical Co., Ltd.
JCR Pharmaceuticals Co., Ltd.

Completed

A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)

Anemia

Japan
University of Michigan Rogel Cancer Center

Recruiting

Gilteritinib for the Treatment of ALK NSCLC

Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8

United States
University of Michigan Rogel Cancer Center

Not yet recruiting

Feasibility of Expressive Writing for Body Image Distress and Anxiety Among Adolescent and Young Adult Cancer Survivors

Body Image | Adolescent Cancer | Young Adult Cancer

United States
University of Michigan Rogel Cancer Center

Recruiting

A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)

Oropharyngeal Cancer | Squamous Cell Carcinoma of the Oropharynx

United States
University of Michigan Rogel Cancer Center

Recruiting

Feasibility and Acceptability of Brief, Telehealth Cognitive Compensatory Training for Pediatric Cancer Patients

Pediatric Cancer

United States
University of Michigan Rogel Cancer Center

Recruiting

Evaluating a Pharmacogenetic Testing Panel in Patients Suspected to be at Increased Risk for Pharmacogenetics-related AEs While Receiving Fluoropyrimidine or Irinotecan Therapy

Cancer

United States
University of Michigan Rogel Cancer Center

Recruiting

CLEAR Care Companion Application

Bladder Cancer | Radical Cystectomy

United States
University of Michigan Rogel Cancer Center

Recruiting

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)

Prostate Cancer | Oligometastatic Disease | Castrate Sensitive Prostate Cancer

United States
University of Michigan Rogel Cancer Center

Recruiting

Optimization of MRI for Radiation Therapy

Cancer Liver | Cancer Brain | Cancer Head &Neck | Cancer Pelvis

United States
University of Michigan Rogel Cancer Center

Active, not recruiting

Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

Gynecologic Cancer

United States
University of Michigan Rogel Cancer Center

Completed

Intestinal Microbiome Modification With Resistant Starch in Patients Treated With Dual Immune Checkpoint Inhibitors

Solid Tumor

United States
University of Michigan Rogel Cancer Center

Withdrawn

Phase IV Multi-arm Study of CDK4/6 Pharmacokinetics in Healthy Volunteers With Known CYP3A4*22 Genotype

CYP3A4*22
University of Michigan Rogel Cancer Center

Completed

Clinical Outcomes, Nutritional Status, Exercise and Psychosocial Factors in Pediatric Hematopoietic Cell Transplant (CONSEPT)

Obesity | Malnutrition

United States
University of Michigan Rogel Cancer Center

Terminated

Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
University of Michigan Rogel Cancer Center

Completed

Improving Quality of Life Using Patient Reported Outcomes Measures Post-operative Via Text Messaging

Gynecologic Cancer

United States
University of Michigan Rogel Cancer Center

Completed

Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer (ABLE)

Urothelial Carcinoma

United States
University of Michigan Rogel Cancer Center

Active, not recruiting

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

Prostate Cancer

United States
University of Michigan Rogel Cancer Center

Terminated

Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia

Chronic Myeloid Leukemia

United States
University of Michigan Rogel Cancer Center

Terminated

Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations

Glioma | High Grade Glioma | Pontine Tumors

United States
University of Michigan Rogel Cancer Center

Completed

Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma

Lymphoma, Non-Hodgkin | Hodgkin's Lymphoma

United States
University of Michigan Rogel Cancer Center

Terminated

Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma

Urothelial Carcinoma

United States
University of Michigan Rogel Cancer Center

Completed

Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab

Breast Cancer

United States
University of Michigan Rogel Cancer Center

Completed

Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Squamous Cell Carcinoma of the Head and Neck

United States
University of Michigan Rogel Cancer Center

Withdrawn

A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML

Leukemia, Chronic Myeloid

United States
University of Michigan Rogel Cancer Center

Completed

Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for High Risk Prostate Cancer

Prostate Cancer

United States
University of Michigan Rogel Cancer Center

Completed

Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer: Concordance Study

Breast Cancer

United States
University of Michigan Rogel Cancer Center

Terminated

Benefits of MPACT in Locally Advanced Head and Neck Cancer Patients Undergoing Chemoradiotherapy

Head and Neck Neoplasms

United States
University of Michigan Rogel Cancer Center

Completed

Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma

Carcinoma, Renal Cell

United States
University of Michigan Rogel Cancer Center

Completed

A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer

Pancreatic Cancer

United States
University of Michigan Rogel Cancer Center

Completed

MRI Study of Radiation-Induced Damage to White Matter and Blood-Brain-Barrier

Brain Neoplasms

United States
University of Michigan Rogel Cancer Center

Completed

Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients

Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

United States
University of Michigan Rogel Cancer Center

Withdrawn

Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma

Cutaneous T Cell Lymphoma

United States
University of Michigan Rogel Cancer Center

Completed

Vessel Sparing Prostate Radiation Therapy

Cancer of the PROSTATE

United States
University of Michigan Rogel Cancer Center

Completed

Using FDG-PET During Radiation Therapy in Non-Small Cell Lung Cancer (HUM15709)

Non-Small Cell Lung Cancer

United States
University of Michigan Rogel Cancer Center

Completed

Effect of Radiation on Tissue for Delayed Breast Reconstruction

Breast Cancer

United States
University of Michigan Rogel Cancer Center

Terminated

Pilot Study of dMRI as a Tool for Early Evaluation of Tumor Response in Diffuse Large B-cell Lymphoma (dMRI)

Diffuse Large B Cell Lymphoma

United States
University of Michigan Rogel Cancer Center

Completed

Study of Etanercept for the Prevention of Complications Resulting From Hematopoietic Stem Cell Transplantation (HSCT)

Graft-Versus-Host Disease

United States
University of Michigan Rogel Cancer Center

Terminated

A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
University of Michigan Rogel Cancer Center

Terminated

Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-Alpha

Chronic Myeloid Leukemia

United States
University of Michigan Rogel Cancer Center

Completed

A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers

Pancreatic Cancer | Biliary Cancer

United States
University of Michigan Rogel Cancer Center

Withdrawn

A Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma

Squamous Cell Carcinoma, Head And Neck

United States
University of Michigan Rogel Cancer Center

Completed

Optimized Intensity Modulated Irradiation for Head and Neck Cancer

Head and Neck Cancer

United States
University of Michigan Rogel Cancer Center

Terminated

A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck

Squamous Cell Carcinoma of the Head and Neck (SCCHN)

United States
University of Michigan Rogel Cancer Center

Completed

Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant

Bronchiolitis Obliterans | Respiratory Distress Syndrome, Adult | Lung Injury, Acute

United States
University of Michigan Rogel Cancer Center

Terminated

Capecitabine and Radiation Therapy in Advanced Pancreatic Cancer

Pancreatic Cancer
University of Michigan Rogel Cancer Center

Completed

A Study of Changes in Hepatic Function During Radiation Therapy Using Hepatobiliary Single Photon Emission Tomography (SPECT)

Hepatocellular Carcinoma

United States
University of Michigan Rogel Cancer Center

Completed

Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate

Prostate Cancer

United States
University of Michigan Rogel Cancer Center

Terminated

Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure

Breast Cancer

United States
Nigel E. Drury

Unknown

Pharmacology of Immunosuppressants Following Heart Transplantation

Heart Transplantation

Australia, United Kingdom
University of Michigan Rogel Cancer Center

Completed

Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC

Small Cell Lung Cancer

United States

Clinical Trials Sponsored by Rigel Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations